Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)
53.90
-1.85 (-3.32%)
Aug 1, 2025, 4:08 PM HKT
HKG:3347 Revenue
Hangzhou Tigermed Consulting had revenue of 1.56B CNY in the quarter ending March 31, 2025, a decrease of -5.79%. This brings the company's revenue in the last twelve months to 6.51B, down -10.12% year-over-year. In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B, down -10.58%.
Revenue (ttm)
6.51B CNY
Revenue Growth
-10.12%
P/S Ratio
8.60
Revenue / Employee
638.89K CNY
Employees
10,185
Market Cap
60.03B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |